TLR9 and neoplasm: To achieve a more effective tumor antigen uptaken by DCs, an MNP-based vaccine has been developed using Fe3O4 nanocluster core loading with the CpG oligodeoxynucleotide (CpG-ODN, a Toll-like receptor 9 agonist) and tumor cell membrane shell decorated with anti-CD205 for preferentially DC recognition (69).